Swedish Orphan Biovitrum AB (publ) (BIOVF, Biotech) Stock Valuation & Fair Value
Mixed on our testsSwedish Orphan Biovitrum AB (publ) (BIOVF, Biotech) trades at a current P/E of 28.7, about 43% below its historical normal valuation, with a forward growth estimate of 25.9% and a PEG of 1.11. Analysts' one-year estimates have been hit 27% of the time. Priced at its historical normal P/E of 50.2 on the same blended earnings, the 2026-11-06 close of $50.19 corresponds to about $87.70 a share. This is a valuation reference, not a price target. The $50.19 close is the one the P/E is read at; the technical context below uses the 2026-11-05 close, $45.72.
How to read these numbers: the PEG ratio and current P/E versus normal P/E.
- Price $45.72 at the Nov 5 close, 2.6% above the 20-day average ($44.58) and 0.3% below the 50-day ($45.87).
- RSI (14) at 61.8.
- 52-week range $34.88 to $49.03: the price is 6.8% below the high and 31.1% above the low.
Valuation flags
- Misses analyst estimates often (55%)
Verdict history
tickerseer's rating moved from favorable on our tests (2026-09-19) to mixed on our tests (2026-11-02). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.
Show all 14 readings
Frequently asked questions
Is Swedish Orphan Biovitrum AB (publ) stock overvalued?
At a current P/E of 28.7 versus its historical normal P/E of 50.2, Swedish Orphan Biovitrum AB (publ) trades about 43% below its typical valuation, with a PEG of 1.11 on 25.9% forward growth. tickerseer currently rates it mixed on our tests.
What is Swedish Orphan Biovitrum AB (publ)'s fair value and PEG?
Swedish Orphan Biovitrum AB (publ) trades at a current P/E of 28.7 against a historical normal P/E of 50.2, a PEG of 1.11, and a forward growth estimate of 25.9%. Priced at its historical normal P/E of 50.2 on the same blended earnings, the 2026-11-06 close of $50.19 corresponds to about $87.70 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Swedish Orphan Biovitrum AB (publ) changed?
tickerseer's rating moved from favorable on our tests (2026-09-19) to mixed on our tests (2026-11-02). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.
Industry: Biotech. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.